USRE33512E - Novel anti-microbial systems containing the magnesium sulfate adduct of 2,2'-dithiobis-pyridine-1,1'-dioxide and a water soluble zinc salt - Google Patents

Novel anti-microbial systems containing the magnesium sulfate adduct of 2,2'-dithiobis-pyridine-1,1'-dioxide and a water soluble zinc salt Download PDF

Info

Publication number
USRE33512E
USRE33512E US07/289,962 US28996288A USRE33512E US RE33512 E USRE33512 E US RE33512E US 28996288 A US28996288 A US 28996288A US RE33512 E USRE33512 E US RE33512E
Authority
US
United States
Prior art keywords
magnesium sulfate
zinc salt
zinc
adduct
sulfate adduct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US07/289,962
Inventor
Jose E. Ramirez
Robert J. Tanko
Mohan Vishnupad
William H. Schmitt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chesebrough Ponds Inc
Original Assignee
Chesebrough Ponds Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chesebrough Ponds Inc filed Critical Chesebrough Ponds Inc
Priority to US07/289,962 priority Critical patent/USRE33512E/en
Application granted granted Critical
Publication of USRE33512E publication Critical patent/USRE33512E/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/48—Medical, disinfecting agents, disinfecting, antibacterial, germicidal or antimicrobial compositions
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
    • A01N59/16—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4933—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having sulfur as an exocyclic substituent, e.g. pyridinethione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations

Definitions

  • This invention relates to novel antimicrobial systems containing a water-soluble, non-ionic pyrethione derivative known chemically as the magnesium sulfate adduct of 2,2'-dithiobis-pyridine-1,1'-dioxide (referred to hereinafter as "the magnesium sulfate adduct") and a water soluble zinc salt. More particularly, it has been found that the presence of a water soluble zinc salt appears to enhance to an unexpected extent the antimicrobial activity of the magnesium sulfate adduct against certain types of microorganisms such, for example, as .[.Staphylococcus epidermidis, Staphylococcus aureus and.]. Pseudomonas aeruginosa.
  • the antimicrobial system of this invention may be incorporated in various useful therapeutic and cleansing compositions such, for example, as surgical scrub compositions, skin disinfectants, mouthwashes, deodorants, hospital cleaners, etc.
  • the magnesium sulfate adduct used in accordance with this invention is a well known broad spectrum antimicrobial agent.
  • a well known commercially available form is sold by Olin Chemicals of Stanford, Conn. under the trade name "OMADINE MDS" which is the trihydrate form.
  • magnesium sulfate adduct used in this invention has broad spectrum antimicrobial activity, it lacks the desired activity against Pseudomonas aeruginosa, the microorganism associated with infection that often follows severe burning of the skin.
  • An object of the invention is to provide novel antimicrobial systems wherein enhanced antimicrobial activity of the magnesium sulfate adduct is effectuated against certain types of microorganisms.
  • Another object of this invention is to provide novel therapeutic and cleansing compositions having incorporated therein the antimicrobial system set forth in the foregoing object.
  • the objects of this invention may be realized by forming an antimicrobial system containing the magnesium sulfate adduct and a water soluble salt.
  • microbiological testing indicates that the activity of magnesium sulfate adduct against Ps. aeruginosa is enhanced in the presence of water soluble zinc salts.
  • the preferred zinc salt used in accordance with this invention is zinc chloride (ZnCl 2 ).
  • Other water soluble zinc salts which may be used are zinc acetate, zinc sulfate, zinc nitrate, zinc phenylsulfonate, etc.
  • the zinc salt should be in an amount from about 1 to about 10, and preferably from about 1 to 1 parts by weight per part of the magnesium sulfate adduct.
  • the magnesium sulfate adduct in general is in an amount from about 0.1 to 1.5% by weight and the zinc salt from about 0.1 to 1% by weight, of the total composition.
  • a most useful antimicrobial composition that may be obtained utilizing the present invention is a surgical scrub compositions employing the antimicrobial system of this invention in an anhydrous foamable base composition.
  • Such surgical scrub compositions have been found useful in killing .[.both Staphylococcus aureus and.]. .Iadd.the .Iaddend.Pseudomonas aeruginosa .[.types of bacteria.]..Iadd.bacterium.Iaddend..
  • the anhydrous foamable base composition contains petroleum jelly, mineral oil and a mild detergent (Sodium cocoyl isethionate).
  • compositions containing the magnesium sulfate adduct and zinc chloride in accordance with the invention were tested for antimicrobial activity and compared with control compositions containing either the magnesium sulfate adduct and/or zinc chloride. These compositions are disclosed in Table I and their antimicrobial activity determined using the "Zone of Inhibition Test" determined.
  • Zone of inhibition test is the relationship between a standard application of a test formulation on a solid agar surface and the resulting zone of inhibited growth of a test organism applied to the agar surface. The larger the zone of growth inhibition, the greater the antimicrobial activity. This test method is used to determine antimicrobial activity in both liquids and solids.
  • compositions of Table I which exemplify of the present invention are:
  • M.I.C. minimal inhibitory concentration
  • the minimal inhibitory concentration is a serial twofold dilution of the test formulation in a broth culture medium which is innoculated with a standardized culture of microorganisms.
  • the amount of test agent that will inhibit visible microbial growth is termed the minimal inhibitory concentration (M.I.C.) level. The lower the amount of test agent, the gretaer the antimicrobial activity.
  • Example 7 formed in accordance with the present invention and controls containing only the magnesium sulfate adduct and/or zinc chloride..].
  • compositions were prepared and evaluated both by the minimum inhibitory concentration method and the zone of inhibition. The results were similar for all salts tested at 1% concentration with Omadine MDS at 0.5%. .[.The activities for all the controls were from 125 to 550 ppm using the M.I.C. method and from 4 to 8 ppm for the combination of zinc salt with Omadine MDS..]. Again, the zone of inhibition was almost non-existent for controls 0-2 mm and 10-14 mm for the combination of the magnesium sulfate adduct and ZnCl 2 combination employed in the present invention.
  • Table 3 there is disclosed a surgical scrub composition Composition I employing the anhydrous foaming base composition of pending application Ser. No. .Iadd.028,072 .Iaddend.containing petroleum jelly, mineral oil, glycerine, TiO 2 and sodium cocoyl isethionate and the magnesium sulfate adduct and ZnCl 2 combination of the present invention and the control base Composition II.
  • the minimum inhibitory concentration activity was enhanced .[.from 125 ppm for the 2% Omadine MDS control Composition II to 2.0 ppm.]. for the Omadine MDS 2%, ZnCl 2 1% in Composition I.[.. This is over.]..Iadd., providing .Iaddend.a .[.sixtyfold.].

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Birds (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This invention relates to novel antimicrobial systems containing a water-soluble, non-ionic pyrethione derivative known chemically as the magnesium sulfate adduct of 2,2'-dithiobis-pyridine-1,1'-dioxide (referred to hereinafter as "the magnesium sulfate adduct") and a water soluble zinc salt.
The antimicrobial systems of this invention may be incorporated in various useful therapeutic and cleansing compositions such, for example, as surgical scrub compositions, skin disinfectants, mouthwashes, deodorants, hospital cleaners, etc.

Description

SUMMARY OF INVENTION
This invention relates to novel antimicrobial systems containing a water-soluble, non-ionic pyrethione derivative known chemically as the magnesium sulfate adduct of 2,2'-dithiobis-pyridine-1,1'-dioxide (referred to hereinafter as "the magnesium sulfate adduct") and a water soluble zinc salt. More particularly, it has been found that the presence of a water soluble zinc salt appears to enhance to an unexpected extent the antimicrobial activity of the magnesium sulfate adduct against certain types of microorganisms such, for example, as .[.Staphylococcus epidermidis, Staphylococcus aureus and.]. Pseudomonas aeruginosa.
The antimicrobial system of this invention may be incorporated in various useful therapeutic and cleansing compositions such, for example, as surgical scrub compositions, skin disinfectants, mouthwashes, deodorants, hospital cleaners, etc.
BACKGROUND OF THE INVENTION
The magnesium sulfate adduct used in accordance with this invention is a well known broad spectrum antimicrobial agent. For example, a well known commercially available form is sold by Olin Chemicals of Stanford, Conn. under the trade name "OMADINE MDS" which is the trihydrate form.
While the magnesium sulfate adduct used in this invention has broad spectrum antimicrobial activity, it lacks the desired activity against Pseudomonas aeruginosa, the microorganism associated with infection that often follows severe burning of the skin.
.[.Examples of additional microorganisms against which it would be desirable to enhance the antimicrobial activity of the pyrithione derivative used in this invention are Staphylococcus aureus and Staphylococcus epidermidis..].
OBJECTS OF THE INVENTION
An object of the invention is to provide novel antimicrobial systems wherein enhanced antimicrobial activity of the magnesium sulfate adduct is effectuated against certain types of microorganisms.
Another object of this invention is to provide novel therapeutic and cleansing compositions having incorporated therein the antimicrobial system set forth in the foregoing object.
GENERAL DESCRIPTION OF THE INVENTION
It has been found that the objects of this invention may be realized by forming an antimicrobial system containing the magnesium sulfate adduct and a water soluble salt.
For example, microbiological testing indicates that the activity of magnesium sulfate adduct against Ps. aeruginosa is enhanced in the presence of water soluble zinc salts.
The preferred zinc salt used in accordance with this invention is zinc chloride (ZnCl2). Other water soluble zinc salts which may be used are zinc acetate, zinc sulfate, zinc nitrate, zinc phenylsulfonate, etc.
In general, it has been found that in order to obtain the desired enhancement of antimicrobial activity in accordance with the present invention the zinc salt should be in an amount from about 1 to about 10, and preferably from about 1 to 1 parts by weight per part of the magnesium sulfate adduct.
In the therapeutic and/or cleansing composition of this invention the magnesium sulfate adduct in general is in an amount from about 0.1 to 1.5% by weight and the zinc salt from about 0.1 to 1% by weight, of the total composition.
It has been found that a most useful antimicrobial composition that may be obtained utilizing the present invention is a surgical scrub compositions employing the antimicrobial system of this invention in an anhydrous foamable base composition. Such surgical scrub compositions have been found useful in killing .[.both Staphylococcus aureus and.]. .Iadd.the .Iaddend.Pseudomonas aeruginosa .[.types of bacteria.]..Iadd.bacterium.Iaddend.. The anhydrous foamable base composition contains petroleum jelly, mineral oil and a mild detergent (Sodium cocoyl isethionate).
SPECIFIC DESCRIPTION OF THE PRESENT INVENTION
In order to illustrate the invention by specific examples a number of compositions containing the magnesium sulfate adduct and zinc chloride in accordance with the invention were tested for antimicrobial activity and compared with control compositions containing either the magnesium sulfate adduct and/or zinc chloride. These compositions are disclosed in Table I and their antimicrobial activity determined using the "Zone of Inhibition Test" determined.
Zone of inhibition test is the relationship between a standard application of a test formulation on a solid agar surface and the resulting zone of inhibited growth of a test organism applied to the agar surface. The larger the zone of growth inhibition, the greater the antimicrobial activity. This test method is used to determine antimicrobial activity in both liquids and solids.
The compositions of Table I which exemplify of the present invention are:
              TABLE I                                                     
______________________________________                                    
SYNERGISTIC EFFECTS OF ZnCl.sub.2 ON                                      
THE ACTIVITY OF THE MAGNESIUM                                             
SULFATE ADDUCT ® vs. PSEUDOMONAS                                      
                    PHYSI-   ZONES (mm)                                   
ACTIVE ING.'S       CAL      vs. PSEUDO-                                  
AND PERCENTAGE      FORM     MONAS                                        
______________________________________                                    
Example                                                                   
       Omadine MDS @ 0.135%                                               
                        Solution 0                                        
Example                                                                   
       Aluminum Chlorohydrate                                             
                        Solution 0                                        
B      (ACH) @ 17.5%                                                      
Example                                                                   
       Omadine MDS @ 0.135%                                               
                        Solution 0                                        
C      ACH @ 17.5%                                                        
Example                                                                   
       Omadine MDS @ 0.135%                                               
                        Solution 7.6                                      
1      (ACH) @ 17.5%                                                      
       ZnCl.sub.2 @ 0.1%                                                  
Example                                                                   
       ZnCl.sub.2 @ 0.1%                                                  
                        Lotion   0                                        
D                                                                         
Example                                                                   
       Omadine MDS @ 0.135%                                               
                        Solution 0                                        
E      ACH @ 17.5%                                                        
Example                                                                   
       Omadine MDS @ 0.135%                                               
                        Solution 8.6                                      
2      ACH @ 17.5%                                                        
       ZnCl.sub.2 @ 0.1%                                                  
Example                                                                   
       Omadine MDS @ 0.135%                                               
                        Solution 0                                        
F                                                                         
Example                                                                   
       Omadine MDS @ 0.135%                                               
                        Solution 5.6                                      
3      ZnCl.sub.2 @ 0.10%                                                 
Example                                                                   
       ZnCl.sub.2 @ 0.10%                                                 
                        Solution 0                                        
G                                                                         
Example                                                                   
       Omadine MDS @ 0.135%                                               
                        Solution 0                                        
H                                                                         
Example                                                                   
       Omadine MDS @ 0.135%                                               
                        Solution 0                                        
I      ACH @ 17.5%                                                        
Example                                                                   
       Omadine MDS @  0.135%                                              
                        Solution 8.3                                      
4      ACH @ 17.5%                                                        
       ZnCl.sub.2 @ 0.10%                                                 
Example                                                                   
       Base Formula Only                                                  
                        Lotion   0                                        
J                                                                         
Example                                                                   
       ZnCl.sub.2 1.0%  Lotion   2.9                                      
K                                                                         
Example                                                                   
       Omadine MDS 0.225%                                                 
                        Lotion   1.9                                      
L                                                                         
Example                                                                   
       Omadine MDS 0.225%                                                 
                        Lotion   11.9                                     
5      ZnCl.sub.2 1.0%                                                    
Example                                                                   
       ZnCl.sub.2 2.0%  Solution 1                                        
M                                                                         
Example                                                                   
       Omadine MDS 0.225                                                  
                        Solution 0.5                                      
N                                                                         
Example                                                                   
       Omadine MD @ 0.5%                                                  
                        Powder   11.3                                     
6      ZnCl.sub.2 2.0%                                                    
______________________________________                                    
 *The magnesium sulfate adduct is sold by Olin Chemicals under the trade  
 name OMADINE MDS.
Another useful determination for evaluating antimicrobial activity is to the minimal inhibitory concentration (M.I.C.) amount. The minimal inhibitory concentration is a serial twofold dilution of the test formulation in a broth culture medium which is innoculated with a standardized culture of microorganisms. The amount of test agent that will inhibit visible microbial growth is termed the minimal inhibitory concentration (M.I.C.) level. The lower the amount of test agent, the gretaer the antimicrobial activity.
.[.In Table 2 there is reported minimal inhibitory concentration values for Example 7 formed in accordance with the present invention and controls containing only the magnesium sulfate adduct and/or zinc chloride..].
                                  TABLE 2                                 
__________________________________________________________________________
FORMULA                                                                   
       ACTIVE ING.'S                                                      
                   PHYSICAL                                               
                          MIMINUM INHIBITORY CONCENTRATION                
NOS.   AND PERCENTAGE                                                     
                   FORM   (PPM) vs. PSEUDOMONAS                           
__________________________________________________________________________
Example O                                                                 
       ZnCl.sub.2 0.1%                                                    
                   Solution                                               
                          No Activity                                     
Example P                                                                 
       Omadine MDS Solution                                               
                          250                                             
       0.135%                                                             
Example 7                                                                 
       Omadine MDS Solution                                               
                           30                                             
       0.135% ZnCl.sub.2                                                  
       0.1%                                                               
__________________________________________________________________________
The results .[.reported in Table 2.]. .Iadd.of experimental analyses .Iaddend.indicated .[.no activity for ZnCl2, activity of 250 ppm for Omadine MDS alone and 30 ppm for the combination of ZnCl2 with Omadine MDS. This indicates.]. an eightfold increase in activity against Pseudomonas aeruginosa for the combination of ZnCl2 with omadine MDS compared to the activity of ZnCl2 alone or Omadine MDS alone.
In still further comparison study compositions were prepared and evaluated both by the minimum inhibitory concentration method and the zone of inhibition. The results were similar for all salts tested at 1% concentration with Omadine MDS at 0.5%. .[.The activities for all the controls were from 125 to 550 ppm using the M.I.C. method and from 4 to 8 ppm for the combination of zinc salt with Omadine MDS..]. Again, the zone of inhibition was almost non-existent for controls 0-2 mm and 10-14 mm for the combination of the magnesium sulfate adduct and ZnCl2 combination employed in the present invention.
In Table 3 there is disclosed a surgical scrub composition Composition I employing the anhydrous foaming base composition of pending application Ser. No. .Iadd.028,072 .Iaddend.containing petroleum jelly, mineral oil, glycerine, TiO2 and sodium cocoyl isethionate and the magnesium sulfate adduct and ZnCl2 combination of the present invention and the control base Composition II.
              TABLE 3                                                     
______________________________________                                    
Formula        Composition I                                              
                           Composition II                                 
______________________________________                                    
Petroleum Jelly                                                           
               31.00       31.00                                          
Mineral Oil    19.50       19.50                                          
Glycerin       5.00        5.00                                           
TiO.sub.2      0.50        0.50                                           
Na Cocoyl Isethionate                                                     
               40.00       42.00                                          
Omadine MDS    2.00        2.00                                           
ZnCl.sub.2 (50% Solution)                                                 
               2.00                                                       
______________________________________
When tested for antimicrobial activity, the minimum inhibitory concentration activity was enhanced .[.from 125 ppm for the 2% Omadine MDS control Composition II to 2.0 ppm.]. for the Omadine MDS 2%, ZnCl2 1% in Composition I.[.. This is over.]..Iadd., providing .Iaddend.a .[.sixtyfold.]. .Iadd.substantial .Iaddend.increase in activity .Iadd.against Pseudomonas aeruginosa compared to Composition II.Iaddend...[.Evidence for synergism was also observed against Staphylococcus aureus, for Composition I activity is 0.003 ppm, while the control Composition II with 2% Omadine is 0.1 ppm. This is a thirty-threefold increase in activity. For Staphylococcus epidermidis, once again the synergism was confirmed, with 0.0007 ppm activity for the 2% Omadine MDS 1% ZnCl2 combination, while the Composition II control is 0.006 ppm. This is an elevenfold increase in activity..].

Claims (5)

What is claimed is:
1. An antimicrobial composition comprising the magnesium sulfate adduct of 2,2'-dithiobis-pyridine-1,1'-dioxide and a water soluble zinc salt, the zinc salt being in an amount from about 1 to 10 parts by weight per part of the antimicrobial adduct.
2. An antimicrobial composition according to claim 1 wherein the zinc salt is selected from the group consisting of zinc chloride, zinc acetate, zinc sulfate, zinc nitrate and zinc phenylsulfonate.
3. An antimicrobial system according to claim 1 wherein the zinc salt is zinc chloride.
4. An antimicrobial composition according to claim 1, 2 or 3 wherein the zinc salt is in an amount of 1 part by weight per part of the microbial adduct.
5. An antimicrobial composition according to claims 1, 2 or 3 wherein the magnesium sulfate adduct is in an amount from about 0.1 to 1.5% by weight and the zinc salt is in an amount from about 0.1 to 1% by weight of the total composition.
US07/289,962 1985-09-11 1988-12-23 Novel anti-microbial systems containing the magnesium sulfate adduct of 2,2'-dithiobis-pyridine-1,1'-dioxide and a water soluble zinc salt Expired - Fee Related USRE33512E (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US07/289,962 USRE33512E (en) 1985-09-11 1988-12-23 Novel anti-microbial systems containing the magnesium sulfate adduct of 2,2'-dithiobis-pyridine-1,1'-dioxide and a water soluble zinc salt

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/774,725 US4654213A (en) 1985-09-11 1985-09-11 Novel anti-microbial systems containing the magnesium sulfate adduct of 2,2'-dithiobis-pyridine-1,1'-dioxide and a water soluble zinc salt
US07/289,962 USRE33512E (en) 1985-09-11 1988-12-23 Novel anti-microbial systems containing the magnesium sulfate adduct of 2,2'-dithiobis-pyridine-1,1'-dioxide and a water soluble zinc salt

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US06/774,725 Reissue US4654213A (en) 1985-09-11 1985-09-11 Novel anti-microbial systems containing the magnesium sulfate adduct of 2,2'-dithiobis-pyridine-1,1'-dioxide and a water soluble zinc salt

Publications (1)

Publication Number Publication Date
USRE33512E true USRE33512E (en) 1991-01-01

Family

ID=25102079

Family Applications (2)

Application Number Title Priority Date Filing Date
US06/774,725 Ceased US4654213A (en) 1985-09-11 1985-09-11 Novel anti-microbial systems containing the magnesium sulfate adduct of 2,2'-dithiobis-pyridine-1,1'-dioxide and a water soluble zinc salt
US07/289,962 Expired - Fee Related USRE33512E (en) 1985-09-11 1988-12-23 Novel anti-microbial systems containing the magnesium sulfate adduct of 2,2'-dithiobis-pyridine-1,1'-dioxide and a water soluble zinc salt

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US06/774,725 Ceased US4654213A (en) 1985-09-11 1985-09-11 Novel anti-microbial systems containing the magnesium sulfate adduct of 2,2'-dithiobis-pyridine-1,1'-dioxide and a water soluble zinc salt

Country Status (10)

Country Link
US (2) US4654213A (en)
EP (1) EP0216558B1 (en)
JP (1) JPS6296402A (en)
AU (1) AU584455B2 (en)
CA (1) CA1276876C (en)
DE (1) DE3685923T2 (en)
ES (1) ES2001673A6 (en)
HK (1) HK34393A (en)
MX (1) MX164791B (en)
ZA (1) ZA866461B (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958462A (en) 1997-05-23 1999-09-28 Mclean; Linsey Therapeutic bath salts and method of use
US20070141172A1 (en) * 2005-12-21 2007-06-21 Robert Baltzell Method of treating bacterial hoof infections of sheep and cattle
US20070191620A1 (en) * 2006-02-03 2007-08-16 Ramirez Jose E Chemical compositions and methods of making them
US20070203354A1 (en) * 2006-02-03 2007-08-30 Ramirez Jose E Chemical Compositions and Methods of Making Them
US7867522B2 (en) 2006-09-28 2011-01-11 Jr Chem, Llc Method of wound/burn healing using copper-zinc compositions
US20110008271A1 (en) * 2009-07-13 2011-01-13 Jr Chem, Llc Rosacea treatments using polymetal complexes
US7927614B2 (en) 2006-02-03 2011-04-19 Jr Chem, Llc Anti-aging treatment using copper and zinc compositions
WO2011094670A1 (en) 2010-02-01 2011-08-04 Presstek, Inc. Lithographic imaging and printing without defects of electrostatic origin
EP2374614A1 (en) 2010-04-09 2011-10-12 Presstek, Inc. Ablation-type lithographic Imaging with enhanced debris removal
US8273791B2 (en) 2008-01-04 2012-09-25 Jr Chem, Llc Compositions, kits and regimens for the treatment of skin, especially décolletage
WO2012158318A1 (en) 2011-05-17 2012-11-22 Presstek, Inc. Ablation-type lithographic printing members having improved exposure sensitivity and related methods
WO2014031828A1 (en) 2012-08-22 2014-02-27 Presstek, Inc. Ablation-type lithographic printing members having improved shelf life and related methods
US8952057B2 (en) 2011-01-11 2015-02-10 Jr Chem, Llc Compositions for anorectal use and methods for treating anorectal disorders
US9427397B2 (en) 2009-01-23 2016-08-30 Obagi Medical Products, Inc. Rosacea treatments and kits for performing them
WO2018039595A1 (en) 2016-08-25 2018-03-01 Presstek, Llc. Dry printing with simplified plate cleaning
WO2018132365A1 (en) 2017-01-11 2018-07-19 Presstek Llc Ablation-type lithographic printing members having improved exposure sensitivity and related methods
US11559053B1 (en) 2016-09-23 2023-01-24 Specialty Sales, LLC Livestock footbath solutions and methods of use

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5186857A (en) * 1988-11-14 1993-02-16 Imaginative Research Associates, Inc. Self-foaming oil compositions and process for making and using same
US4931204A (en) * 1988-11-14 1990-06-05 Imaginative Research Associates, Inc. Self-foaming oil compositions and process for making and using same
WO1990011343A1 (en) * 1989-03-21 1990-10-04 Imaginative Research Associates, Inc. Self-foaming oil compositions and process for making and using same
JPH06509112A (en) * 1991-07-18 1994-10-13 ザ、プロクター、エンド、ギャンブル、カンパニー liquid deodorant composition
DE4200499A1 (en) * 1992-01-10 1993-07-15 Bode Chemie Gmbh & Co DISINFECTANT
US5227156A (en) * 1992-04-14 1993-07-13 Amway Corporation Use of zinc compounds to stabilize a thiazolinone preservative in an anti-dandruff shampoo
FR2739775B1 (en) * 1995-10-16 1997-11-21 Oreal DEODORANT COMPOSITION COMPRISING A WATER-SOLUBLE SALT OF ZINC AS AN ODOR-ABSORBING AGENT
US5863524A (en) * 1997-03-26 1999-01-26 Church & Dwight Co., Inc. Transparent bicarbonate salt containing deodorant cosmetic stick product
CN100341408C (en) * 1999-06-25 2007-10-10 阿奇化工公司 Pyrithione antimicrobial agents synergized with silver, copper or zinc ions
AU2005200050B2 (en) * 1999-06-25 2008-04-03 Arch Chemicals, Inc. Pyrithione biocides enchanced by silver, copper, or zinc ions
US7455851B1 (en) * 1999-06-25 2008-11-25 Arch Chemicals, Inc. Pyrithione biocides enhanced by silver, copper, or zinc ions
US7026308B1 (en) 1999-06-25 2006-04-11 The Procter & Gamble Company Topical anti-microbial compositions
AU2008202828B8 (en) * 1999-06-25 2011-08-11 Arch Chemicals, Inc. Pyrithione biocides enhanced by silver, copper, or zinc ions
US7674785B2 (en) * 2000-06-22 2010-03-09 The Procter & Gamble Company Topical anti-microbial compositions
DE10196338D2 (en) * 2001-04-12 2004-04-29 Meissner Dieter Foam, process for making foam and using foam
BRPI0309444A2 (en) * 2002-04-22 2016-07-12 Arch Chem Inc use of zinc ionophore behavior materials
WO2003088957A1 (en) * 2002-04-22 2003-10-30 The Procter & Gamble Company Personal care compositions comprising a zinc containing material in an aqueous surfactant composition
US8491877B2 (en) * 2003-03-18 2013-07-23 The Procter & Gamble Company Composition comprising zinc-containing layered material with a high relative zinc lability
US9381382B2 (en) * 2002-06-04 2016-07-05 The Procter & Gamble Company Composition comprising a particulate zinc material, a pyrithione or a polyvalent metal salt of a pyrithione and a gel network
US20050202984A1 (en) * 2003-03-18 2005-09-15 Schwartz James R. Composition comprising zinc-containing layered material with a high relative zinc lability
US9381148B2 (en) * 2003-03-18 2016-07-05 The Procter & Gamble Company Composition comprising particulate zinc material with a high relative zinc lability
US20040191331A1 (en) * 2003-03-18 2004-09-30 The Procter & Gamble Company Composition comprising particulate zinc materials having a defined crystallite size
US20040213751A1 (en) * 2003-03-18 2004-10-28 Schwartz James Robert Augmentation of pyrithione activity or a polyvalent metal salt of pyrithione activity by zinc-containing layered material
US7910118B2 (en) 2004-07-16 2011-03-22 Bannister Dennis R Skin treatment
US20120195944A9 (en) * 2009-08-12 2012-08-02 Amy Michelle Capretta Rinse-Off Care Products and Consumer Product Line-ups Comprising Same
MX2014001891A (en) 2011-08-15 2014-05-27 Procter & Gamble Methods of enhancing skin hydration and improving non-diseased skin.
GB201211702D0 (en) 2012-07-02 2012-08-15 Reckitt Benckiser Llc Sprayable aqueous alcoholic microbicidal compostions comprising zinc ions
GB201211701D0 (en) 2012-07-02 2012-08-15 Reckitt Benckiser Llc Aqueous alcoholic microbicidal compositions comprising zinc ions
EP2925125A1 (en) 2012-11-30 2015-10-07 Reckitt & Colman (Overseas) Limited Microbicidal personal care compositions comprising metal ions

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3890434A (en) * 1971-10-18 1975-06-17 Olin Corp Hair and antiseptic formulations containing adducts of bis-(2-pyridyl-1-oxide) disulfide
JPS5415939A (en) * 1978-07-01 1979-02-06 Hokko Chem Ind Co Ltd Underwater antifouling coating compound
US4152431A (en) * 1977-09-22 1979-05-01 William H. Rorer, Inc. Compositions and method of use
US4161526A (en) * 1978-07-20 1979-07-17 Sterling Drug Inc. Zinc salt prevention or removal of discoloration in pyrithione, pyrithione salt and dipyrithione compositions
US4163783A (en) * 1977-09-22 1979-08-07 Klein Robert W Synergistic compositions and method of use to treat inflammation
US4235873A (en) * 1979-03-30 1980-11-25 Dermik Laboratories Antiperspirant-deodorant compositions
US4410446A (en) * 1979-06-07 1983-10-18 Petrolite Corporation Zinc oxide dispersions by decomposition of zinc acetate
JPS6016973A (en) * 1983-07-06 1985-01-28 Kao Corp Method for producing 2-mercaptopyridine-N-oxide/polyvalent metal salt fine particles

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3785985A (en) * 1971-04-21 1974-01-15 Colgate Palmolive Co Cosmetic and textile-treating compositions
EP0174980A4 (en) * 1984-03-01 1987-10-08 Vernon Erk Use of manganese compound in the preparation of a medicament for the treatment of hypothyroidism.
JPH0625121B2 (en) * 1985-03-28 1994-04-06 花王株式会社 Method for producing fine particles of 2-mercaptopyridine-N-oxide polyvalent metal salt
AU6175586A (en) * 1985-09-11 1987-03-12 Chesebrough-Pond's Inc. Petroleum jelly, mild detergent anhydrous base compositions

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3890434A (en) * 1971-10-18 1975-06-17 Olin Corp Hair and antiseptic formulations containing adducts of bis-(2-pyridyl-1-oxide) disulfide
US4152431A (en) * 1977-09-22 1979-05-01 William H. Rorer, Inc. Compositions and method of use
US4163783A (en) * 1977-09-22 1979-08-07 Klein Robert W Synergistic compositions and method of use to treat inflammation
JPS5415939A (en) * 1978-07-01 1979-02-06 Hokko Chem Ind Co Ltd Underwater antifouling coating compound
US4161526A (en) * 1978-07-20 1979-07-17 Sterling Drug Inc. Zinc salt prevention or removal of discoloration in pyrithione, pyrithione salt and dipyrithione compositions
US4235873A (en) * 1979-03-30 1980-11-25 Dermik Laboratories Antiperspirant-deodorant compositions
US4410446A (en) * 1979-06-07 1983-10-18 Petrolite Corporation Zinc oxide dispersions by decomposition of zinc acetate
JPS6016973A (en) * 1983-07-06 1985-01-28 Kao Corp Method for producing 2-mercaptopyridine-N-oxide/polyvalent metal salt fine particles

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Chemical Abstract 69:343387w (1968); Okomoto, et al. *
Chemical Abstract 80:91617x (1974); Elkhouly, et al. *
Chemical Abstract 87:161376p (1977); Wedig et al. *
Chemical Abstract 88:177003w (1978); Wedig, et al. *
Chemical Abstract 91:32995y (1979); Giloor, et al. *
The Merck Index 9th Ed. (1976) pp. 1307 1309; Merck & Co. *
The Merck Index 9th Ed. (1976)-pp. 1307-1309; Merck & Co.

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958462A (en) 1997-05-23 1999-09-28 Mclean; Linsey Therapeutic bath salts and method of use
US7670629B2 (en) 2005-12-21 2010-03-02 Robert Baltzell Method of treating bacterial hoof infections of sheep and cattle
US20070141172A1 (en) * 2005-12-21 2007-06-21 Robert Baltzell Method of treating bacterial hoof infections of sheep and cattle
US20110178318A1 (en) * 2006-02-03 2011-07-21 Ramirez Jose E Methods of making bimetal complexes
US8148563B2 (en) 2006-02-03 2012-04-03 Jr Chem, Llc Chemical compositions and methods of making them
US7687650B2 (en) 2006-02-03 2010-03-30 Jr Chem, Llc Chemical compositions and methods of making them
US20070203354A1 (en) * 2006-02-03 2007-08-30 Ramirez Jose E Chemical Compositions and Methods of Making Them
US7897800B2 (en) 2006-02-03 2011-03-01 Jr Chem, Llc Chemical compositions and methods of making them
US7927614B2 (en) 2006-02-03 2011-04-19 Jr Chem, Llc Anti-aging treatment using copper and zinc compositions
US20070191620A1 (en) * 2006-02-03 2007-08-16 Ramirez Jose E Chemical compositions and methods of making them
US7867522B2 (en) 2006-09-28 2011-01-11 Jr Chem, Llc Method of wound/burn healing using copper-zinc compositions
US8505730B2 (en) 2008-01-04 2013-08-13 Jr Chem, Llc Compositions, kits and regimens for the treatment of skin, especially décolletage
US8273791B2 (en) 2008-01-04 2012-09-25 Jr Chem, Llc Compositions, kits and regimens for the treatment of skin, especially décolletage
US9427397B2 (en) 2009-01-23 2016-08-30 Obagi Medical Products, Inc. Rosacea treatments and kits for performing them
US20110008271A1 (en) * 2009-07-13 2011-01-13 Jr Chem, Llc Rosacea treatments using polymetal complexes
WO2011094670A1 (en) 2010-02-01 2011-08-04 Presstek, Inc. Lithographic imaging and printing without defects of electrostatic origin
EP2374614A1 (en) 2010-04-09 2011-10-12 Presstek, Inc. Ablation-type lithographic Imaging with enhanced debris removal
US8952057B2 (en) 2011-01-11 2015-02-10 Jr Chem, Llc Compositions for anorectal use and methods for treating anorectal disorders
WO2012158318A1 (en) 2011-05-17 2012-11-22 Presstek, Inc. Ablation-type lithographic printing members having improved exposure sensitivity and related methods
WO2014031828A1 (en) 2012-08-22 2014-02-27 Presstek, Inc. Ablation-type lithographic printing members having improved shelf life and related methods
WO2018039595A1 (en) 2016-08-25 2018-03-01 Presstek, Llc. Dry printing with simplified plate cleaning
US11559053B1 (en) 2016-09-23 2023-01-24 Specialty Sales, LLC Livestock footbath solutions and methods of use
WO2018132365A1 (en) 2017-01-11 2018-07-19 Presstek Llc Ablation-type lithographic printing members having improved exposure sensitivity and related methods

Also Published As

Publication number Publication date
EP0216558A2 (en) 1987-04-01
US4654213A (en) 1987-03-31
JPH0442361B2 (en) 1992-07-13
CA1276876C (en) 1990-11-27
DE3685923D1 (en) 1992-08-13
JPS6296402A (en) 1987-05-02
ZA866461B (en) 1987-04-29
DE3685923T2 (en) 1993-02-25
ES2001673A6 (en) 1988-06-01
HK34393A (en) 1993-04-16
MX164791B (en) 1992-09-24
EP0216558A3 (en) 1988-08-17
AU584455B2 (en) 1989-05-25
EP0216558B1 (en) 1992-07-08
AU6185186A (en) 1987-03-12

Similar Documents

Publication Publication Date Title
USRE33512E (en) Novel anti-microbial systems containing the magnesium sulfate adduct of 2,2'-dithiobis-pyridine-1,1'-dioxide and a water soluble zinc salt
US5707993A (en) Glycine anhydride dimethylol as a biocide and preservative
US7247295B2 (en) Use of 1,2-decandiol for combating germs causing body odor
US5428050A (en) Synergistic water soluble preservative compositions of biocidal mixtures
AU683719B2 (en) Synergistic antimicrobial compositions containing a halogenated acetophenone and an organic acid
US4098877A (en) Antimicrobial composition (enhanced activity from combination of phenol and a quaternary compound)
WO2009094198A1 (en) Liquid preservative compositions
JP3637281B2 (en) Disinfectant composition and disinfecting method using the same
EP0230698B1 (en) Use of an ester compound as a temporary microbicide
CA2135427A1 (en) Method and composition for controlling the growth of microorganisms
CA2284543C (en) Biocidal composition and use
US5292776A (en) Microbial inhibiting compositions and their use
EP0236119A1 (en) Preservative compositions and uses thereof
JP2903582B2 (en) Industrial antibacterial and antialgal compositions
EP0651608B1 (en) Synergistic antimicrobial compositions containing 2-(2-bromo-2-nitroethenyl)furan
US5352706A (en) Method and composition for controlling the growth of microorganisms
JPH1129408A (en) Disinfectant and disinfectant for pathogenic Legionella spp.
JPH02169501A (en) Control of formaldehyde
FI72254B (en) ENPRODUKT FOER UTBREDNING PAO HUDEN FOER HYGIENI OCH / ELLER EFOHINDRANDE AV INFLAMMATIONER
JP2001181113A (en) Industrial disinfectants and preservatives and their disinfection and preservative methods
JPH11199408A (en) Disinfecting composition, disinfecting power accelerating method and disinfecting method
CA2121622A1 (en) Process and composition for inhibiting microbial growth
TH2446A (en) A microbial antiseptic ingredient

Legal Events

Date Code Title Description
REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees